ASCO 2022 Conference Coverage
ASCO 2022 Efficacy and Safety of Bosutinib in Later-Line Patients With CML: A Sub-Analysis From the Phase 4 BYOND Trial
By
ASCO 2022 Conference Coverage
FEATURING
Carlo Gambacorti-Passerini
By
ASCO 2022 Conference Coverage
FEATURING
Carlo Gambacorti-Passerini
Login to view comments.
Click here to Login
